ABSTRACT. Phenylacetylglutamine (PAG), the amino hippurate nitrogen and/or PAG nitrogen can substitute for urea acid acetylation product of phenylacetate (or phenylbutyr-nitrogen in patients receiving low nitrogen intakes has not been ate after P-oxidation) was evaluated as a waste nitrogen studied. product in patients with inborn errors of urea synthesis. A We propose to examine the hypothesis that PAG nitrogen boy with carbamyl phosphate synthetase deficiency receiv-alone can replace urea nitrogen as a vehicle for waste nitrogen ing a low nitrogen intake excreted 80-90% of administered synthesis and excretion in patients on low protein intakes. phenylacetate or phenylbutyrate as PAG. The amount of Theoretical considerations. To estimate the requirement for PAG nitrogen excreted varied from 38-44% of his dietary hippurate and/or PAG nitrogen synthesis and excretion, it is nitrogen, similar to the relationship between urea nitrogen necessary to know urine urea nitrogen excretion in normal and dietary nitrogen found in normal subjects receiving low subjects as a function of dietary nitrogen. dietary nitrogen. With few exceptions, neither phenylaceAlthough there are many studies of the effect of variations of tate nor phenylbutyrate accumulated in plasma. Treatment dietary nitrogen intake or urine nitrogen excretion, there are, with relatively high dose phenylacetate or phenylbutyrate curiously, very few such studies where urine urea nitrogen has (0.5-0.6 g/kg/d) resulted in normal daytime levels of glu-been measured in normal subjects receiving varying nitrogen tamine. These data suggest that PAG may replace urea as intakes. a waste nitrogen product when phenylbutyrate is adminisCalloway and Margan (6) reported that on dietary nitrogen tered at a dose that yields PAG nitrogen excretion equal intakes (g/d) of 6.5-7.5 (40.6-46.9 g of proteinld) normal adult 47% of their dietary nitrogen. Assuming complete conversion to its amino acid conjugate, the oral administration of 18 g of Abbreviations sodium phenylacetate should result in the excretion of 3.23 g of PAC nitrogen, an amount that would completely replace urea PAG, phenylacetylglutamine nitrogen as a vehicle for waste nitrogen excretion in subjects receiving low protein intakes. There appear to be no studies of normal children receiving varying nitrogen intakes in whom urine urea nitrogen excretion was measured. However, it is possible to calculate from a report The physiologic problem faced by a patient with inborn errors of Waterlow (7) that children (6-24 mo of age) receiving a diet of urea synthesis is excretion of waste nitrogen, i.e. dietary of 0.2 g/kg/d of nitrogen/d (1 2 5 g/kg/d of protein) mcrete 0.094 nitrogen not used for net protein synthesis or excreted in other g of urea nitrogen/kg/d, 47% of dietary nitrogen. To acrete ways (stool, skin, etc.). Treatment of such patients by modifying 0.094 g/kg/d of PAG nitrogen would require 0.524 g/kg/d of the quantity and quality of nitrogen intake may reduce the sodium phenylacetate. This represents a 36% improvement in requirements for urea synthesis and thereby be helpful (especially nitrogen excretion as compared to the combination of sodium in patients with significant residual ureagenic capacity). Dietary benzoate and sodium phenylacetate, each at a dose of 0.25 g/kg/ therapy alone has been unsuccessful in severely affected patients d, which would result in the excretion of 0.069 g/kg/d of nitrogen (1, 2).
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(0.025 g as hippurate nitrogen and 0.045 g as PAG nitrogen). That other nitrogen-containing compounds may for These theoretical considerations suggest that, on a molar basis, urea nitrogen may be adduced from the report by Lewis (3) , who ~hen~lacetate (mol &, 158) is twice as effective as benzoate described a stoichiometric relationship between the decrease in because PAG contains two nitrogen atoms as compared to the urine urea nitrogen and appearance of urine hippurate nitrogen one nitrogen atom of h i~~u r a t e .
Phen~lacetate, however has a in a normal subject given sodium benzoate.
disadvantage as consequence of its offensive odor [it is one of The use of amino acid acylation pathways has been successfully several ~hen~lalkanoic acids, apart from ~h e n~l b u t~r i c acid, exploited in empiric studies of patients with inborn errors of urea secreted as a defensive weapon by the stinkpot turtle (811. Theresynthesis (4, 5) . Treatment with sodium benzoate (0.25 g/kg/d) fore, sodium ~henylbutyrate (mol &, 186), which is known to and sodium phenylacetate (0.25 g/kg/d), respectively, activate be p-oxidized in viva to ~hen~lacetate (9) , may serve as a Prothe synthesis and excretion of hippurate and PAG, both of which drug for ~hen~lacetate. may serve as waste nitrogen products. The degree to which Three studies were performed. In the first, the stoichiometry phenylacetate, 12 g (64.5 mmol) of sodium phenylbutyrate, and 14 g (75.2 mmol) of sodium phenylbutyrate. His daily diet during the three periods consisted of 1 1 g of natural protein, 1 1 g of an essential amino acid mixture (nitrogen density 12%), and 4.5 g (25.7 mmol) of citrulline. The total nitrogen intake was calculated to be 3.84 g, which included 0.4 g of nitrogen in the gelatin capsules containing the drugs and the one third of administered citrulline nitrogen that enters the free amino acid pool. Total urinary nitrogen, urea nitrogen, and ammonium nitrogen were measured in each period.
In the second study, the overnight fasting plasma levels of phenylacetate, phenylbutyrate, and PAG were measured in patients with various urea cycle disorders receiving varying dosages of sodium phenylbutyrate.
In the third study, the diurnal variation in plasma levels of glutamine, phenylacetate, phenylbutyrate, PAG, and ammonium was studied in five patients with deficiencies of carbamyl phosphate synthetase or ornithine transcarbamylase, four of whom were treated with phenylaceate or phenylbutyrate.
Plasma levels of phenylacetate and PAG were measured by reverse phase HPLC (Waters, Milford, MA) after precipitation with methanol. The technique includes isocratic elution using the mobile phase of 0.005 M phosphoric acid in 10% methanol at a flow rate of 1.2 mL/min with spectrophotometric detection at 2 18 nm. Urine levels were similarly measured after appropriate dilution. The detection limits in plasma and urine for phenylbutyrate, phenylacetate, and PAG were 0.05, 0.03, and 0.02 mmol/L, respectively.
Phenylbutyrate levels in plasma were also similarly measured except for the mobile phase, which consisted of 0.005 mol/L phosphoric acid in 40% methanol. PAG (for use as an external standard) was synthesized from phenylacetyl chloride and glutamine (10) . Plasma amino acids were measured by automated column chromatography (model 6300; Beckman, Palo Alto, CA). Urinary creatinine was measured by the Jaffe reaction after absorption and elution from Lloyds reagent (1 I). Plasma ammonium was measured by visible spectrophotometry using the indophenol reaction after separation of the ammonium ion by a batch cation exchange technique (1 2). Urine glucuronides were measured using the naptharesorcinol reagent (1 3). Urinary nitrogen was measured by the Kjeldahl method previously described (14) and urinary urea and ammonium were measured as described by Chaney and Marbach (1 5).
These studies were approved by The Johns Hopkins Joint Committee on Clinical Investigation. Table 1 compares the stoichiometry between phenylacetate or phenylbutyrate administration and urinary excretion of PAG. The amount of PAG excreted was a function of phenylacetate or phenylbutyrate dose; between 80 and 90% of the predicted amount of PAG synthesized is excreted. That these may be minimum excretion values is suggested by the coeficient of variation of the creatinine excretion over the 9 d, which was 14%. Table 1 also demonstrates that when PAG excretion is expressed as PAG nitrogen, it accounts for at least 38-44% of dietary nitrogen intake. Phenylacetate, phenylbutyrate, or total glucuronide excretion in the urine did not exceed 1% of the administered drug in any period. Table 2 shows the excretion of total urinary nitrogen, urea appears to be completely oxidized to phenylacetate and that phenylacetate is completely, or nearly so, conjugated with glutamine. That complete conjugation of the drugs occurs may be further adduced by the insignificant amount of unchanged drugs or their esters in urine and by the lack of accumulation in overnight fasting plasma (Table 2) . Table 1 To evaluate whether phenylacetate, phenylbutyrate, or PAG accumulate, overnight fasting plasma levels were measured in 10 patients receiving oral sodium phenylbutyrate at doses varying from 0.306 to 0.65 g/kg/d (Table 3) . With only two exceptions, overnight fasting plasma levels of phenylbutyrate and phenylacetate were below the limits of detectability. Plasma levels of PAG were below 0.5 mmol/L. Figure 1 shows the diurnal variation of plasma glutamine level in two untreated females with ornithine transcarbamylase deficiency and four treated patients with a deficiency of either carbamyl phosphate synthetase or ornithine transcarbamylase. Plasma glutamine levels returned to normal during the day in each treated patient regardless of the overnight fasting glutamine levels, which were 0.67, 1. In patients receiving sodium phenylbutyrate, the mean (a1 SD) diurnal plasma levels of phenylacetate, phenylbutyrate, and PAG (excluding overnight fasting values described earlier) were 0.37 + 0.3, 0.17 + 0.25, and 1.42 + 0.9 1 mmol/L, respectively. It has been apparent for a number of years that hyperammonemia in patients with inborn errors of urea synthesis is always associated with high plasma glutamine levels (1, 16) . It also has been shown in such patients that plasma glutamine levels increase before the onset of symptomatic hyperammonemia (17) . Figure  1 suggests that phenylacetate or phenylbutyrate are effective in maintaining normal nitrogen homeostasis as manifested by maintenance of plasma glutamine levels at normal or near normal levels during the day without significant accumulation of drugs or their reaction products.
RESULTS
Our data support the hypothesis that high doses of phenylacetate or phenylbutyrate will result in the synthesis and excretion of PAG nitrogen similar to the amount of urea nitrogen that is excreted in normal subjects on a low-protein diet. Unlike urea synthesis, which will increase or decrease in proportion to nitrogen intake, PAG nitrogen synthesis is a function of the dose of phenylacetate or phenylbutyrate. Therefore, the appropriate dose will be a function of dietary nitrogen and nitrogen retention. Under circumstances of avid nitrogen retention (e.g. premature or full-term infants and patients on marginal nitrogen intakes) it may be possible to induce riegative nitrogen balance by administering high-dose phenylacetate or phenylbutyrate. For example, a nutritionally stable 6-y-old boy with ornithine transcarbamylase deficiency receiving an essential amino acid diet developed alopecia, periorbital edema, and hypoproteinemia shortly after phenylbutyrate was substituted for benzoate (unpublished observations). His nutritional deficiencies promptly resolved when protein was added to his diet.
Whether phenylacetate or phenylbutyrate may be helpful in the management of other nitrogen accumulation diseases, such as hepatic encephalopathy or chronic renal disease, remains to be tested. Although both the liver and the kidney have the requisite enzyme activity for glutamine conjugation (1 8, 19) , phenylacetyl CoA ligase and acyl-CoA:L-glutamine N-acyl-transferase, it is not certain that either organ alone will have the requisite activity or, in the case of chronic renal disease, whether PAG accumulation may limit the usefulness of these drugs. 
